# A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

> **NCT00009737** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1987 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT00009737
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 1987 (ACTUAL)
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00009737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00009737, "A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00009737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*